Gothenburg, Sweden, September 27, 2016 - Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced the appointment of Carlos de Sousa as Immunicum's Chief Executive Officer effective on October 1, 2016. Mr. de Sousa brings more than 25 years of relevant experience in the international pharmaceutical and biotech industries, including senior positions at Nycomed/Takeda, Pfizer, Novartis, BBB Therapeutics, Newron Pharmaceuticals and, most recently, as Chief Business Officer at Zealand Pharma in Denmark.
Mr. de Sousa has a long international career, honing his expertise on the business side of the pharma/biotech industry both in big pharma and the smaller biotech arenas. Prior to Zealand Pharma, as Chief Business Officer at BBB Therapeutics, Mr. de Sousa was instrumental in driving strategy design and implementation for out-licensing of phase I and phase II compounds and implementing the U.S. market and pricing research for the two lead compounds.
His experience in leading and transitioning companies from early clinical stage to bringing a product to market is highlighted by his ability to build key partnerships and comes to Immunicum with an extensive global network of contacts.
Mr. de Sousa is a Medical Doctor by training, having earned his medical degree at School of Medicine, University of Lisbon and holds an Executive MBA from the Stern School of Business, New York University.
"We welcome Carlos's experience and leadership to Immunicum," said Agneta Edberg, Chairman of the Board. "In his new role as chief executive, he will be responsible for driving the development of INTUVAX, and our other cancer immunotherapies, in order to bring innovative therapeutic solutions to critical patient needs and create a profitable business for Immunicum's shareholders. His results-oriented approach and ability to think strategically will play a pivotal role in the coming years while helping us grow towards profitability".
Mr. de Sousa will replace Jamal El-Mosleh, Immunicum's CEO since September 2007, who will now work with Mr. de Sousa to assure a smooth and seamless transition.
"Immunicum has made significant progress since the Company's inception and especially over the last few years, due, in part, to the great efforts of our former CEO, Jamal El-Mosleh. We are now in a very pivotal stage in the Company's existence and the Board felt it was time to seek new competencies for the further development and capitalization of our lead product INTUVAX. Jamal El-Mosleh has achieved a lot during his tenure as CEO and we are truly grateful for his efforts," continued Ms. Edberg, Chairman of the Board, "We are unanimous in our excitement for the future of Immunicum."
For more information, please contact:
Agneta Edberg, Chairman of the Board, Immunicum
Ph: +46 (0)70 555 75 18
The company's Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31
About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST). Immunicum is listed on First North Premier. www.immunicum.se
The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the company's contact person on September 27, 2016 at 08:30 CET
